Evidence map›Paper›PMID 42707991›Full record

ArticleTheranostics2026

Novel nastorazepide-based radioligands demonstrate effective cholecystokinin-2 receptor targeting with potential for theranostic applications.

Lennart Bohrmann, Doroteja Novak, Marko Kroselj, Raghuvir H Gaonkar, Francesca Porto, Melpomeni Fani, Petra Kolenc, Marko Anderluh, Rosalba Mansi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lennart BohrmannDivision of Radiopharmaceutical Chemistry, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
Doroteja NovakDivision of Nuclear Medicine, University Medical Centre Ljubljana, Zaloška 7, 1000 Ljubljana, Slovenia.
Marko KroseljDivision of Nuclear Medicine, University Medical Centre Ljubljana, Zaloška 7, 1000 Ljubljana, Slovenia.
Raghuvir H GaonkarDivision of Radiopharmaceutical Chemistry, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
Francesca PortoDivision of Radiopharmaceutical Chemistry, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
Melpomeni FaniDivision of Radiopharmaceutical Chemistry, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
Petra KolencDivision of Nuclear Medicine, University Medical Centre Ljubljana, Zaloška 7, 1000 Ljubljana, Slovenia.
Marko AnderluhDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia.
Rosalba MansiDivision of Radiopharmaceutical Chemistry, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiolabeled gastrin antagonists are emerging as a new tool for the diagnosis and treatment of cholecystokinin-2 receptor (CCK2R) expressing tumors such as medullary thyroid carcinoma and small cell lung cancer, overcoming limitations of agonist-based ligands. In this study, the CCK2R antagonist nastorazepide (Z-360) was used as a targeting scaffold in combination with either a peptidic (NPP) or a hydrophilic polysaccharide (NPS) linker and the chelators DOTA and DOTAGA, yielding four novel radioligands. These were evaluated alongside the reference minigastrin analogs DOTA-PP-F11 and DOTA-MGS5. Methods: All ligands were synthetized Results: Conclusion: [¹⁷⁷Lu]Lu-DOTAGA-NPP emerged as the most promising lead compound, combining high tumor uptake, favorable tumor-to-organ ratios, and excellent

Indexed as

BenzodiazepinonesRadiopharmaceuticalsReceptor, Cholecystokinin BTheranostic NanomedicineAnimalsCell Line, TumorFemaleHumansIndium RadioisotopesLigandsLutetiumMiceRadioisotopesTissue DistributionBenzodiazepinonesIndium RadioisotopesLigandsLutetiumLutetium-177RadioisotopesRadiopharmaceuticalsReceptor, Cholecystokinin Bcholecystokinin-2 receptor (CCK2R) antagonistsnastorazepidepeptide receptor radionuclide therapyradioligandsSPECT/CT

Identifiers

PMID42707991
PMCPMC13549144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.